巴瑞替尼成功治疗小儿难治性大疱性类天疱疮
Successful treatment of infantile refractory bullous pemphigoid with baricitinib.
作者信息
Zhou Weinan, Tan Yidong, Chen Xuanyi, Zhang Wenqing, Sun Zhe, Shen Yihang, Yao Zhirong, Cheng Ruhong, Gu Yan
机构信息
Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
出版信息
Australas J Dermatol. 2024 Dec;65(8):642-646. doi: 10.1111/ajd.14345. Epub 2024 Jul 19.
Infantile bullous pemphigoid (BP) is a rare autoantibody-mediated skin disorder. We report the effective treatment of a 6-month-old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.
婴儿大疱性类天疱疮（BP）是一种罕见的自身抗体介导的皮肤疾病。我们报告了一例6个月大的BP婴儿患者，在使用类固醇和静脉注射免疫球蛋白治疗失败后，使用JAK抑制剂巴瑞替尼进行有效治疗的病例。该患者实现了完全缓解，停用了所有药物且未出现任何复发。据我们所知，这是巴瑞替尼用于婴儿BP患者的首例病例。
Zotero 插件